The market celebrated the first quarter results of Gilead Sciences, Inc.(NASDAQ:GILD) by sending the shares of the company to an all-time high on Friday.
Gilead Sciences Inc. said Monday that the Food and Drug Administration rejected two marketing applications for HIV treatments, citing quality control problems at the company's manufacturing facilities.
Gilead Sciences, Inc. (NASDAQ:GILD) reported a relatively rare earnings miss in the first quarter on May 2. The biotech announced earnings of $0.48 per share while analysts were expecting $0.50 per share.
New York, NY -- (SBWIRE) -- 05/07/2013 -- Growing Stock Report expands its NASDAQ Decliners Weekly Watch List adding Gilead Sciences Inc. (NASDAQ:GILD), Express Scripts Holding Company (NASDAQ:ESRX), and Life Technologies Corporation ...
Gilead Sciences, Inc. (NASDAQ:GILD) recently disclosed in its Global Healthcare Conference that the company has launched its Stribild tablet in the United States back in August of last year and since then the company recorded under 100 million in terms ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that detailed results from four Phase 3 clinical trials (NEUTRINO, FISSION, POSITRON and FUSION) evaluating sofosbuvir, the company's investigational once-daily nucleotide NS5B inhibitor for the ...
In our new rank based on the most recent short interest data from NASDAQ, Monster Beverage Corp (NASD: MNST) has taken over the position of #26 most shorted Nasdaq 100 component, from Gilead Sciences, Inc. (NASD: GILD) which is now in the # spot.
Apr 22, 2013 (ACCESSWIRE-TNW via COMTEX) -- NEW YORK, April 22, 2013 -Bestdarnpennystocks.com, one of the leaders in providing investment alerts on U.S.
Gilead Sciences, Inc. (NASDAQ: GILD): By the end of last trading session, Gilead Sciences (NASDAQ: GILD) dropped US$0.72 (or 1.31%) to US$54.43 with about 13.33 million shares exchanged hands for the session, compared to its average volume of ...
Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. To see all exchange delays, please see disclaimer.